This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Patrys Limited. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Stephanie Ute Brandlein: Innovator in Antibody Development
Introduction
Stephanie Ute Brandlein is a notable inventor based in Zellingen, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic and diagnostic applications. Her work focuses on innovative solutions for treating various forms of cancer.
Latest Patents
Stephanie holds 1 patent related to LM-antibodies, functional fragments, and the LM-1 target antigen. The patent describes the invention of LM-1 antibodies, functional fragments, modified and variant forms, as well as nucleic acid and other compositions. These innovations are particularly useful in treatment and diagnostic methods, including a method for treating metastasis of neoplasia, tumors, or cancer by administering LM-1 antibodies or functional fragments to affected subjects.
Career Highlights
Stephanie is currently associated with Patrys Limited, where she continues to advance her research and development efforts. Her work has the potential to significantly impact cancer treatment protocols and improve patient outcomes.
Collaborations
She collaborates with esteemed colleagues such as Frank Schoenen and Heinz Peter Vollmers, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Stephanie Ute Brandlein's contributions to antibody development exemplify the vital role of inventors in advancing medical science. Her innovative work holds promise for improving cancer treatment and diagnostics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile